1-formyl-2,5-dimethyl-pyrrole | 97142-87-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-formyl-2,5-dimethyl-pyrrole
• 英文别名: 1-Formyl-2,5-dimethyl-pyrrol；N-formyl-2,5-dimethylpyrrole；2,5-Dimethylpyrrole-1-carbaldehyde
• CAS: 97142-87-5
• 化学式: C₇H₉NO
• 分子量: 123.155
• InChiKey: KKFHQUWEGXSOOD-UHFFFAOYSA-N

物化性质

• 沸点：
  224.1±43.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-formyl-2,5-dimethyl-pyrrole 生成 2,5-二甲基-1H-吡咯-3-甲醛
  参考文献：
  名称：

  Alessandri; Passerini, Gazzetta Chimica Italiana, 1921, vol. 51, p. I 282

  摘要：

  DOI：
• 作为产物：
  描述：

  2,5-己二酮 在 对甲苯磺酸 、 formamide 作用下， 以 水 、 苯 为溶剂， 生成 1-formyl-2,5-dimethyl-pyrrole
  参考文献：
  名称：

  Preparation of N-acyl-2,5-dimethylpyrroles from amides and

  摘要：

  N-酰基-2,5-二甲基吡咯烷酮及其制备方法。该方法涉及加热丙酮基丙酮和酰胺的混合物。随后的反应是一种缩合反应，水被分解出来。

  公开号：

  US04511725A1

文献信息

• 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES
  申请人：——

  公开号：US20010007873A1

  公开（公告）日：2001-07-12

  This present invention relates to compounds of the formula 1 wherein G, R 1 and R 2 are defined as in the specification, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system and other disorders.

  这项发明涉及公式1中定义的化合物，其中G、R1和R2如规范中所定义，以及含有它们的药物组合物，以及它们在治疗和预防中枢神经系统和其他疾病中的用途。
• Synthese de pyrroles et d'oxazoles par pyrolyse de N-(hydroxy-2′ ethyl) amino-3 propenoate
  作者：Catherine Pale-Grosdemange、Josselin Chuche

  DOI：10.1016/s0040-4020(01)81018-8

  日期：1989.1

  pyrolysis of various N-(2′-hydroxyethyl)-3-amino propenoates 1–6 and N-(2′-hydroxy-2′-phenyl ethyl)-3-amino propenoate 7–9 at 390°–420°C leads respectively to formylpyrroles 11–16 and benzoylpyrroles 17–19 and, in some cases, to substituted oxazoles 36–39. The results are best explained by the intermediate formation of dicarbonyl derivative followed either by an intramolecular thermal crotonisation

  各种N-（2'-羟基乙基）的气体热解PHAS -3-氨基propenoates 1 - 6和N-（2'-羟基-2'-苯基乙基）-3-氨基丙烯酸7 - 9在390℃-420 ℃，引线分别formylpyrroles 11 - 16和benzoylpyrroles 17 - 19，并且在一些情况下，为了取代的恶唑36 - 39。通过中间形成二羰基衍生物，然后在分子内进行热巴豆化反应或将偶氮甲ine叶立德分子进行6π电环化，可以最好地解释该结果。
• PHARMACEUTICAL USES FOR NOS INHIBITORS
  申请人：——

  公开号：US20020151572A1

  公开（公告）日：2002-10-17

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (N-NOS) inhibitors: (a) alone or in combination with another active agent for the treatment of psoriasis; (b) in combination with an antiinflammatory agent for the treatment of inflammatory disorders; (c) in combination with a narcotic analgesic (e.g., opiates such as morphine or demerol) for the treatment of pain; (d) alone or in combination with other active agents for the enhancement of cognition; and (e) alone or in combination with other active agents for the treatment of sleep disorders such as apnea, narcolepsy and insomnia.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药用途。具体而言，涉及使用NOS抑制剂，特别是选择性神经元NOS（N-NOS）抑制剂：（a）单独或与另一活性剂结合用于治疗牛皮癣；（b）与抗炎药物结合用于治疗炎症性疾病；（c）与麻醉镇痛剂（例如吗啡或度冷丁等阿片类药物）结合用于治疗疼痛；（d）单独或与其他活性剂结合用于增强认知功能；以及（e）单独或与其他活性剂结合用于治疗呼吸暂停、白天疲劳和失眠等睡眠障碍。
• New pharmaceutical combinations for NOS inhibitors
  申请人：Pfizer Inc

  公开号：US20040229911A1

  公开（公告）日：2004-11-18

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂活性的化合物的新药物用途。具体地，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一种活性剂联合使用，特别是SSRI或NK-1受体拮抗剂，用于治疗可以通过改变昼夜节律来达到或促进治疗的疾病或病况。这些疾病和病况的例子包括失明、肥胖症、季节性情感障碍、双相情感障碍、时差反应、昼夜节律睡眠障碍、睡眠剥夺、睡眠障碍、REM睡眠障碍、嗜睡症、睡眠-觉醒周期障碍、嗜睡症和与轮班工作或不规则工作时间表相关的睡眠障碍、夜尿症和不宁腿综合症。
• [EN] NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS<br/>[FR] NOUVELLES COMBINAISONS PHARMACEUTIQUES POUR LES INHIBITEURS DE NOS
  申请人：PFIZER PROD INC

  公开号：WO2000071107A2

  公开（公告）日：2000-11-30

  The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.

  本发明涉及表现为一氧化氮合酶（NOS）抑制剂的化合物的新药物用途。具体而言，涉及使用NOS抑制剂，特别是选择性神经元NOS（nNOS）抑制剂，单独或与另一活性剂，特别是SSRI或NK-1受体拮抗剂结合使用，治疗可以通过改变昼夜节律来实现或促进的疾病或状况。这些疾病和状况的例子包括失明，肥胖症，季节性情感障碍，双相情感障碍，时差反应，昼夜节律睡眠障碍，睡眠剥夺，睡眠障碍，REM睡眠障碍，嗜睡症，睡眠-清醒周期障碍，嗜睡症和与轮班或不规则工作时间表相关的睡眠障碍；夜尿症和不安腿综合症。